Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy.
Gamma synuclein
Nicotine acetylcholine receptor
Oral cancer
Signal transduction
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
12
2019
accepted:
06
07
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
The mechanisms of neuronal protein γ-synuclein (SNCG) in the malignancy of oral squamous cell carcinoma (OSCC) are not clear. This study tested the hypothesis that SNCG is involved in nicotine-induced malignant behaviors of OSCC. The effect of nicotine on SNCG expression and epithelial-to-mesenchymal transition (EMT) markers were examined. Short hairpin RNA (shRNA) and an antagonist specific for α7-nicotine acetylcholine receptors (α7-nAChRs) were used to examine the role of α7-nAChRs in mediating the effects of nicotine. Knockdown of SNCG in nicotine-treated cells was performed to investigate the role of SNCG in cancer malignancy. The in vivo effect of nicotine was examined using a nude mouse xenotransplantation model. Nicotine increased SNCG expression in a time- and dose-dependent manner. Nicotine treatment also increased E-cadherin and ZO-1 and decreased fibronectin and vimentin expression. After specific knockdown of α7-nAChRs and inhibition of the PI3/AKT signal, the effect of nicotine on SNCG expression was attenuated. Silencing of SNCG abolished nicotine-induced invasion and migration of OSCC cells. The xenotransplantation model revealed that nicotine augmented tumor growth and SNCG expression. Nicotine upregulated SNCG expression by activating the α7-nAChRs/PI3/AKT signaling that are participated in nicotine-induced oral cancer malignancy.
Sections du résumé
BACKGROUND
BACKGROUND
The mechanisms of neuronal protein γ-synuclein (SNCG) in the malignancy of oral squamous cell carcinoma (OSCC) are not clear. This study tested the hypothesis that SNCG is involved in nicotine-induced malignant behaviors of OSCC. The effect of nicotine on SNCG expression and epithelial-to-mesenchymal transition (EMT) markers were examined.
METHODS
METHODS
Short hairpin RNA (shRNA) and an antagonist specific for α7-nicotine acetylcholine receptors (α7-nAChRs) were used to examine the role of α7-nAChRs in mediating the effects of nicotine. Knockdown of SNCG in nicotine-treated cells was performed to investigate the role of SNCG in cancer malignancy. The in vivo effect of nicotine was examined using a nude mouse xenotransplantation model.
RESULTS
RESULTS
Nicotine increased SNCG expression in a time- and dose-dependent manner. Nicotine treatment also increased E-cadherin and ZO-1 and decreased fibronectin and vimentin expression. After specific knockdown of α7-nAChRs and inhibition of the PI3/AKT signal, the effect of nicotine on SNCG expression was attenuated. Silencing of SNCG abolished nicotine-induced invasion and migration of OSCC cells. The xenotransplantation model revealed that nicotine augmented tumor growth and SNCG expression.
CONCLUSION
CONCLUSIONS
Nicotine upregulated SNCG expression by activating the α7-nAChRs/PI3/AKT signaling that are participated in nicotine-induced oral cancer malignancy.
Identifiants
pubmed: 32669976
doi: 10.1186/s12935-020-01401-w
pii: 1401
pmc: PMC7350738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
300Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1454-1463
pubmed: 28167231
J Oncol. 2011;2011:693424
pubmed: 21772846
PLoS One. 2016 Feb 24;11(2):e0149120
pubmed: 26909550
J Periodontal Res. 2012 Jun;47(3):299-308
pubmed: 22489671
Clin Cancer Res. 2011 Jun 1;17(11):3533-41
pubmed: 21444681
Expert Opin Drug Discov. 2009 Sep;4(9):907-21
pubmed: 23480539
Exp Neurol. 1999 Dec;160(2):515-22
pubmed: 10619569
BMC Cancer. 2008 Aug 11;8:229
pubmed: 18694499
Mol Cancer Ther. 2015 Sep;14(9):2112-20
pubmed: 26184482
Toxicol Appl Pharmacol. 2013 Feb 1;266(3):459-69
pubmed: 23219715
J Dent Res. 2016 Apr;95(4):439-45
pubmed: 26661712
Nature. 2009 Mar 26;458(7237):534-7
pubmed: 19252481
Cancer. 2004 Jul 1;101(1):58-65
pubmed: 15221989
Cancer Res. 2004 Jul 1;64(13):4539-46
pubmed: 15231664
Neurobiol Dis. 2018 Sep;117:170-180
pubmed: 29859873
J Oral Maxillofac Surg. 2003 Jul;61(7):751-8
pubmed: 12856245
Med Sci Monit. 2014 Dec 05;20:2550-5
pubmed: 25479371
Oncogene. 2003 Oct 23;22(48):7593-9
pubmed: 14576821
Oncogene. 2007 Aug 30;26(40):5900-10
pubmed: 17369845
Oncotarget. 2017 Aug 24;8(43):75065-75075
pubmed: 29088845
Oncotarget. 2018 Jan 24;9(14):11734-11751
pubmed: 29545933
FASEB J. 2007 Nov;21(13):3419-30
pubmed: 17567567
PLoS One. 2012;7(12):e51967
pubmed: 23300583
Oncol Rep. 2014 Mar;31(3):1480-8
pubmed: 24399025
PLoS One. 2015 Mar 26;10(3):e0122295
pubmed: 25811377
Front Oncol. 2017 Apr 26;7:78
pubmed: 28491820
J Oncol. 2016;2016:9650481
pubmed: 26981122
Cancer Res. 2003 Feb 1;63(3):664-73
pubmed: 12566312
Cells. 2019 Jan 23;8(2):
pubmed: 30678058
Cancer Res. 2005 Sep 1;65(17):7635-43
pubmed: 16140929
Br J Pharmacol. 2018 Jun;175(11):1957-1972
pubmed: 28726253
Hum Genet. 1998 Jul;103(1):106-12
pubmed: 9737786
J Pathol. 2019 Apr;247(5):629-640
pubmed: 30582157
Nat Med. 2015 Apr;21(4):373-82
pubmed: 25799226
Cancer. 2000 May 1;88(9):2154-63
pubmed: 10813729
J Neurosci Res. 2013 Feb;91(2):161-6
pubmed: 23150342
J Pathol. 2009 Mar;217(4):507-15
pubmed: 19009586
Cancer Biol Ther. 2006 May;5(5):511-7
pubmed: 16582591
Cancer Sci. 2008 Oct;99(10):1924-32
pubmed: 19016751
Biochim Biophys Acta. 2009 Feb;1794(2):282-90
pubmed: 19013262